Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gov't to Formulate Basic Policy for New Healthcare System for Elderly in FY2002
March 11, 2002
- NCC Forecasts Survival Rates for Cancer Will Double by 2015
March 11, 2002
- Each Drug Firm Has Tie-ups with 18 Others: FTC Survey
March 11, 2002
- Novartis Foundation Provides Support for 53 Researchers
March 11, 2002
- REGULATORY NEWS IN BRIEF
March 11, 2002
- DIAGNOSTIC NEWS IN BRIEF
March 11, 2002
- OTS NEWS IN BRIEF
March 11, 2002
- NHI Price Revision in April Will Hit Drug Companies Hard: Mr Fujiyama of FPMAJ
March 11, 2002
- Kuraya Sanseido Aims at Consolidated Sales of \1,330 Bil. in FY2004
March 11, 2002
- GE Maker Lost the Game: Mr Sawai
March 11, 2002
- Hokuriku: Sales Increase by 22% to \24.9 Bil.
March 11, 2002
- New SMO Industry Organization to Be Created in April
March 11, 2002
- Otsuka's POCARI Drink Inhibits Increases in Blood Viscosity
March 11, 2002
- SSRI 20th Anniversary Seminar
March 11, 2002
- Sunstar to Report Anti-allergic Effects of Persimmon Leaf Extract
March 11, 2002
- RAD-AR Proposes to Korosho to Use Reexamination Data to Construct Database
March 11, 2002
- Glaucoma Testing Not Conducted in 80% of Municipalities in Tokyo
March 11, 2002
- BUSINESS NEWS IN BRIEF
March 11, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 11, 2002
- 7 Drugs Approved, Including Sivelestat
March 11, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…